A portable surface acoustic wave (SAW)-generating system, a transdermal patch, and methods of treatment with improved transdermal administration of drugs are provided. Application of the transdermal patch comprising a therapeutically effective amount of the cannabis id, such as a cannabis drug, to the skin in combination with SAW results in a synergistic effect on delivery and absorption of the at least one drug as compared to topical administration of the drug via the transdermal patch without the surface acoustic waves generated by the portable SAW-generating system.

A method of preparing medical composition including hemp or Cannabis full plant extracts, cannabinoids, and one or more pharmaceutically acceptable excipients containing active pharmaceutical ingredients (APIs) can produce suppositories, patches, cream, lipstick or other skin care cosmetic. Cannabis, hemp plant chemicals and APIs can be delivered to one's bloodstream. The suppository composition is formulated for effective absorption through the mucosal membrane. The suppository is useful for the administration of medicine to treat pain, nausea, post-operative ileus, and/or inflammatory bowel diseases in patients with nausea, vomiting, other conditions preventing swallowing, or conditions wherein suppository administration is required.

A topical pharmaceutical or cosmetic formulation is disclosed, comprising two polymer membranes enclosing probiotic bacteria having antimicrobial activities against skin pathogens sandwiched therebetween, one of the membranes being semipermeable and having a pore size which does not allow penetration of the bacteria, and medical and cosmetic uses thereof. Preferably the probiotic bacteria are of the order Lactobacillales, most preferably of the strain L. plantarum 8P-A3 (DSM 32835).

A device for the delivery of an agent to an intestinal site has a backing element, a mucoadhesive element for adhering the device to the intestinal site, and a reservoir comprising the agent. The mucoadhesive element includes a polymer, an opposing surface having the capacity to adhere to the intestinal site, and a population of passageway(s) extending from the reservoir to the opposing surface for delivery of the agent from the reservoir to the intestinal site, each of the passageway(s) having a minimum diameter greater than 10 microns, the diameter being determined by cryogenic scanning electron microscopy after 30 minutes of hydration at 20° C. in phosphate buffered saline at pH 6.5.

The present disclosure relates to compositions, methods of use and methods of manufacturing of transdermal delivery systems, patches, vehicles and devices including an iontophoretic transdermal delivery system, patch, vehicle or device used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Aspects of the disclosure provided herein relate to compositions and methods for providing a drug delivery through a transdermal patch. Some other embodiments relate to a transdermal drug delivery patch comprising a bottom layer comprising a skin side liner, a middle layer comprising a gel, a top layer comprising a release liner, wherein the adhesive or gel comprises at least one drug capable of modulating histamine in a subject. Some other embodiments provided herein relate to a transdermal drug delivery system for delivery of at least one drug into a tissue membrane of a subject. Some other embodiments relate to a transdermal drug delivery patch comprising a bottom layer comprising a skin side liner, a middle layer comprising a gel/adhesive, a top layer comprising a release liner, wherein the gel comprises at least one drug capable of modulating histamine receptors in a subject.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

The present invention relates to a patch comprising a high content of rivastigmine per unit area, which can be continuously administered for a long time. The rivastigmine patch according to the present invention is capable of continuous release of rivastigmine for a long period of time, preferably 3 days, more preferably 4 days or more after attachment, and has excellent physical and chemical stability.

The present invention relates to a patch comprising a high content of rivastigmine per unit area, which can be continuously administered for a long time. The rivastigmine patch according to the present invention is capable of continuous release of rivastigmine for a long period of time, preferably 3 days, more preferably 4 days or more after attachment, and has excellent physical and chemical stability.

An article. The article includes a polymer foam having a first major surface and a second major surface; and discrete domains of a therapeutic composition at least partially surrounded by the polymer foam; wherein an exterior surface of each discrete domain substantially conforms to a portion of the first major surface of the polymer foam; wherein the article comprises a first major surface and a second major surface; and wherein a portion of the first major surface of the polymer foam and the exterior surfaces of discrete domains form the first major surface of the article.